British pharmaceuticals firm pays $3bn to end probes
The Guardian
British pharmaceuticals firm pays $3bn to end probes by American authorities into sale and marketing of drugs such as Avandia and Wellbutrin
British drugs giant GlaxoSmithKline has agreed to pay $3bn (£1.9bn) to settle a series of criminal and civil investigations by the US authorities into the sales and marketing of some of its best-known products.
Among the cases the payment will settle are a US justice department probe into the marketing of diabetes drug Avandia, which has been linked to heart attack risks. Avandia was withdrawn from the European market last year and sales were limited in the US.










